| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_259045c6eba6e2c5d338b84e0a88b571 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6689789562bfc98c3ff763976de30e68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0184756f2bfc4ff38589133d0dd93f90
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f86d0bc6a9ad373f2752e87e78376e70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3ae8a9bb293f242ab322fcf04aff6cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11e50b4a591013032764bd5b581ea76a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be91a6a3d5102b92af323288974e0c6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7f970db00bfd7decb260b6e1bbd104c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45c9f991643b1ff94815d9cb61ab3e08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0762b8a4516e0f80a5c4ddc2d293341b |
| publicationDate |
2016-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160008827-A |
| titleOfInvention |
Pharmaceutical composition for enhancing sensitivity to anticancer drugs comprising expression or activity inhibitor of kallikrein 6 as an active ingredient |
| abstract |
The present invention relates to a pharmaceutical composition for enhancing anticancer sensitivity and anticancer drugs containing KLK6 (kallikrein 6) as an active ingredient as an active ingredient, and a method for screening an anticancer drug resistance inhibitor or an anticancer drug sensitivity enhancer for an anticancer drug resistant cancer Specifically, auranofin reduced the survival rate of KLK6-deficient gastric cancer cells. The expression of KLK6 due to the activity of p53 increased autophagy induction, and gene blockade by promoter methylation reduced autophagy And the drug sensitivity was reduced. Accordingly, it has been confirmed that the present invention can be used for an anticancer agent sensitivity enhancer and a screening method thereof by inhibiting autophagy activity using KLK6 and LC3B expression or activity inhibitors. |
| priorityDate |
2014-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |